HER2DX Genomic Testing Outperforms Traditional Histopathology in Predicting Neoadjuvant Therapy Response for HER2-Positive Breast Cancer
Posted innews Oncology Pathology & Lab Medicine/Bệnh học

HER2DX Genomic Testing Outperforms Traditional Histopathology in Predicting Neoadjuvant Therapy Response for HER2-Positive Breast Cancer

This comprehensive analysis validates the HER2DX genomic assay as a robust tool that reflects tumor biology and independently predicts pathologic complete response, offering clinicians a precise instrument for personalizing treatment in early-stage HER2-positive breast cancer.